HongTianjin Pharmaceutical (NQ: 833746) was established in 2007 and is located in Li Shizhen Pharmaceutical Industrial Park, Qichun County, Hubei Province, covering an area of about 20,000 square meters. The company focuses on the research and development and production of innovative anti-tumor and high-end veterinary drug raw materials, and its products are mainly biofermentation.
anti-tumor drugs field, combining new drugs with generic drugs, such as ixapilon, bortezomib, vinorrebin tartaric acid and other products. Among them, vinorrebin tartaric acid has obtained drug registration approval documents and has passed the CEP and GMP certification .
vinorelbine tartaric acid, chemical name: 3′, 4′-dihydrogen-4′-deoxy-8′-norvinblastine ditartrate. Chemical structural formula: C45H54N4O8·2C4H6O6, vinorelbine (NVB) is half-synthetic vinca alkaloid, and its mechanism of action is basically the same as vinclastine (VLB) and vincristine (VCR). It mainly blocks the formation of microtubule during cell mitosis, causing cell division to stop in the meso-mitosis phase, and is a specific drug for cell cycle. This product has little impact on the microtubule of nerve cells, so it has low neurotoxicity. It is clinically used in non-small cell lung cancer , metastatic breast cancer, advanced ovarian cancer, malignant lymphoma , etc.
Currently, there are 19 tartaric acid vinyl ruibin preparation manufacturers in China, 5 of which have signed procurement contracts with Hongzhong, including Sinopharm Yixin Pharmaceutical Co., Ltd., Shanxi Pude Pharmaceutical Co., Ltd. , etc.
tartaric acid vinyl ruibin injection manufacturers include 9 companies including Jiangsu Hausen Pharmaceutical (subsidiary of Hansen Pharmaceutical (03692), Qilu Pharmaceutical (Hainan), Shuanglu Pharmaceutical (SZ:002038). Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 70%. Currently, sales exceed 100 million yuan.
veterinary medicine field, mainly products such as mirbexime, ceramidin, and teraxin.
As one of the company's core products, it has passed the US FDA certification twice in the past two years. Mirbemycin oxime is mainly used to treat antibody internal and external parasites. This drug was developed by Japan Sankyo Co., Ltd. Competitors include: Lizhu Group , Borui Pharmaceutical , Qingdao Kangdien Pharmaceutical Company, Prolo Pharmaceutical (000739), Zhongnong Warwick (NQ: 835911), Wuhan Kmek Biopharma Technology Co., Ltd., Hubei Maikes Practice Technology Co., Ltd., etc.
Lizhu Group (000513) 2020 semi-annual report shows that its Mirbet oxime revenue is 46.85 million yuan and its production capacity is 2 tons.
HongTian Pharmaceutical currently has most of its revenue from anti-cancer drugs, and pet drugs account for a small part, but the company's plan is: to take high-end pet drugs as the core of development in the future. Most of the customers of
are overseas, facing Europe, the United States and Japan, because currently only vinorelbine tartaric acid and pet drug Mirbexime have passed the domestic GMP and the US FDA certification respectively, and more than 70% of these products are in the United States and Europe.
's customers include:
LotuspharmaceuticalCo., Ltd., Taiwan's Meishi Pharmaceutical, acquired by the American generic drug giant Alvogen;
KRKA, the largest pharmaceutical company in in , in 2014, KRKA ranked 16th in the global generic drug industry;
INTASPHARMACEUTICALSLTD, India Biology Generic drug ;
Qilu Pharmaceutical (Hainan) Co., Ltd., a well-known domestic generic drug company;
RUEBELMEDPREPARATY, Belarusian pharmaceutical company;
Hangzhou Pre Chemical Co., Ltd., provides exclusive marketing promotion for domestic pharmaceutical companies in foreign markets;
JointStockCompanyPharmasyncez;
Chemwerth.
Due to the small market size of the company's main products, the company's revenue has been very small, but it is growing rapidly. The company has been losing money in the past, with a lot of liabilities and very little cash on its account; however, as the company's orders continue to increase, the scale effect has gradually formed, and the previous large capital investment has basically been completed, the company's profits have increased explosively in 2021, and finally turned from loss to profit.
According to the development of the first half of the year, it is expected to reach a net profit of about 30 million yuan throughout the year. It can be said that it takes ten years to become famous.
The number of employees in the company is also increasing significantly, which shows that it is indeed improving.
According to Chairman Zhang Wenkai: In the next few years, our business should be a blowout development. If we are not prepared, we may miss an opportunity. So this year, especially in the talent reserve, our company has added 30% of talents this year, so I believe that welcoming a rapid development in the future can lay a very important foundation for the company.
Review of the development history of Hongzhong Pharmaceutical, which shows that the development of small and micro industrial enterprises is difficult to achieve, and it is difficult to get a return after more than ten years of investment. Zesheng Technology, another pharmaceutical company on the New Third Board, has been engaged in innovative drugs for 20 years, and it is still unknown whether it can be launched. Only by sticking to the original aspiration can you see the dawn.
[Special Note] The data and information in the article come from company financial reports, securities research reports, industry reports, corporate official websites, public accounts, Baidu Encyclopedia and other public information. I strive to report the content and views of the article objectively and fairly, but do not guarantee its accuracy, completeness, timeliness, etc. The information or opinions in the article do not constitute any investment advice. Investors are responsible for any investment behavior determined independently. I shall not be liable for any direct or indirect losses arising from the use of the content of this article. More in-depth analysis of , Beijing Stock Exchange and the New Third Board, welcome to follow @Anfu Shuang , which focuses on the BASE
According to the development of the first half of the year, it is expected to reach a net profit of about 30 million yuan throughout the year. It can be said that it takes ten years to become famous.
The number of employees in the company is also increasing significantly, which shows that it is indeed improving.
According to Chairman Zhang Wenkai: In the next few years, our business should be a blowout development. If we are not prepared, we may miss an opportunity. So this year, especially in the talent reserve, our company has added 30% of talents this year, so I believe that welcoming a rapid development in the future can lay a very important foundation for the company.
Review of the development history of Hongzhong Pharmaceutical, which shows that the development of small and micro industrial enterprises is difficult to achieve, and it is difficult to get a return after more than ten years of investment. Zesheng Technology, another pharmaceutical company on the New Third Board, has been engaged in innovative drugs for 20 years, and it is still unknown whether it can be launched. Only by sticking to the original aspiration can you see the dawn.
[Special Note] The data and information in the article come from company financial reports, securities research reports, industry reports, corporate official websites, public accounts, Baidu Encyclopedia and other public information. I strive to report the content and views of the article objectively and fairly, but do not guarantee its accuracy, completeness, timeliness, etc. The information or opinions in the article do not constitute any investment advice. Investors are responsible for any investment behavior determined independently. I shall not be liable for any direct or indirect losses arising from the use of the content of this article. More in-depth analysis of , Beijing Stock Exchange and the New Third Board, welcome to follow @Anfu Shuang , which focuses on the BASE
